The DOI matches its Crossref record; 241 of the 244 references it cites were found in a registry or an index.
Neuroinflammation in Alzheimer's disease
Open accessAbstract
Increasing evidence suggests that Alzheimer's disease pathogenesis is not restricted to the neuronal compartment, but includes strong interactions with immunological mechanisms in the brain. Misfolded and aggregated proteins bind to pattern recognition receptors on microglia and astroglia, and trigger an innate immune response characterised by release of inflammatory mediators, which contribute to disease progression and severity. Genome-wide analysis suggests that several genes that increase the risk for sporadic Alzheimer's disease encode factors that regulate glial clearance of misfolded proteins and the inflammatory reaction. External factors, including systemic inflammation and obesity, are likely to interfere with immunological processes of the brain and further promote disease progression. Modulation of risk factors and targeting of these immune mechanisms could lead to future therapeutic or preventive strategies for Alzheimer's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“since there is a strong correlation between immune activation and oxidative damage in neurodegenerative disease [42,43,44]”
From ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease (2020) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Chronic low-grade inflammation contributes to both the onset and progression of AD and PD through microglial activation and pro-inflammatory cytokine release, accelerating neuronal injury [4].”
From What Are the Key Biological Pathways Through Which Lifestyle Factors Influence Neurodegeneration? (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This aligns with biological evidence highlighting the roles of diet and circadian regulation in modulating neuroinflammation and glymphatic clearance [4,5].”
From What Are the Key Biological Pathways Through Which Lifestyle Factors Influence Neurodegeneration? (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“During early stages of AD, microglia contribute to Αβ clearance15”
From Amyloid-β induces lipid droplet-mediated microglial dysfunction via the enzyme DGAT2 in Alzheimer’s disease (2025) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Converging lines of evidence from human genetics, neuroimaging and post-mortem brain tissue studies suggest that microglia are major contributors to molecular and phenotypic changes, including synaptic loss and Aβ clearance, in the AD brain [4].”
From Heterozygous expression of the Alzheimer’s disease-protective PLCγ2 P522R variant enhances Aβ clearance while preserving synapses (2022) · cites this paper as [4]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Likewise, microglia, the brain-resident immunocompetent macrophages, also recognize Aβ oligomers via receptors such as CD36, toll-like receptor 4 (TLR4) and TLR6 and triggering receptor expressed on myeloid cells 2 (TREM2), acquiring specific AD-associated phenotypes [14,15,16].”
From Emerging Role of miR-21-5p in Neuron–Glia Dysregulation and Exosome Transfer Using Multiple Models of Alzheimer’s Disease (2022) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In AD, however, a subset of astrocytes undergoes reactive transformation, adopting inflammatory and metabolically altered states that compromise synaptic support and promote neurotoxicity (Heneka et al., 2015; Nassar et al., 2022).”
From Cell-specific MicroRNA networks orchestrate the pathogenesis of Alzheimer’s disease (2026) · cites this paper as Heneka et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In AD, these networks become maladaptive, leading to sustained inflammation, impaired synaptic support, defective myelination (Nasrabady et al.; 2018, Zhou et al., 2022), and breakdown of the blood-brain barrier (BBB), ultimately amplifying neurodegeneration (Heneka et al., 2015; Sweeney et al., 2018).”
From Cell-specific MicroRNA networks orchestrate the pathogenesis of Alzheimer’s disease (2026) · cites this paper as Heneka et al., 2015
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Receptors on microglia can bind Aβ fibrils, driving an inflammatory response similar to the M1 (proinflammatory) phenotype observed outside the central nervous system [84].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [84]
The cited source says what the claim attributes to it.
In the citing paper
“The reactive gliosis, encompassing microgliosis and astrogliosis, are prevalent neuropathological hallmarks observed in the brains of both human AD and mouse models of Aβ amyloidosis8,15,16.”
From Effects of SPI1-mediated transcriptome remodeling on Alzheimer's disease-related phenotypes in mouse models of Aβ amyloidosis (2024) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“Amyloid-associated gliosis is consistently observed in the brains of AD patients15 and amyloidosis mouse models8,16.”
From Effects of SPI1-mediated transcriptome remodeling on Alzheimer's disease-related phenotypes in mouse models of Aβ amyloidosis (2024) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“Increasing clinical evidence suggests that neuroinflammation functions as a vital factor in AD pathogenesis (2)”
From Understanding monocyte-driven neuroinflammation in Alzheimer’s disease using human cortical organoid microphysiological systems (2025) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“altered microglial function has been implicated in the progression of AD”
From Heterozygous expression of the Alzheimer’s disease-protective PLCγ2 P522R variant enhances Aβ clearance while preserving synapses (2022) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, Aβ may initiate microglial activation, resulting in microglial migration to plaques, phagocytosis, and enzymatic degradation of Aβ [37].”
From Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy (2021) · cites this paper as [37]
The cited source says what the claim attributes to it.
In the citing paper
“Astrocytes become reactive and inflammatory, while microglia transition into chronically activated states that can amplify neuroinflammation (Heneka et al., 2015; Sofroniew and Vinters, 2010).”
From Cell-specific MicroRNA networks orchestrate the pathogenesis of Alzheimer’s disease (2026) · cites this paper as Heneka et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“Microglia, the brain's primary immune cells, play a dual and stage-dependent role in AD, initially contributing to Aβ clearance but transitioning into a chronically reactive, pro-inflammatory state under persistent pathological stress (Hansen et al., 2017; Heneka et al., 2015).”
From Cell-specific MicroRNA networks orchestrate the pathogenesis of Alzheimer’s disease (2026) · cites this paper as Heneka et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“Neuroinflammation is a prominent feature of the neuropathology of Alzheimer’s disease (AD), in addition to β-amyloid (Aβ) plaques, tau-containing neurofibrillary tangles (NFT), and synaptic dysfunction followed by neurodegeneration [1].”
From 25-Hydroxycholesterol amplifies microglial IL-1β production in an apoE isoform-dependent manner (2020) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Emerging evidence indicates that neuroinflammation, mediated by activated glial cells, plays a fundamental role in the pathogenesis and neurodegeneration of AD [1].”
From 25-Hydroxycholesterol amplifies microglial IL-1β production in an apoE isoform-dependent manner (2020) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“While amyloid-β plaques and TAU tangles have long been recognized as pathological hallmarks of AD, emerging research highlights the critical role of neuroinflammation in disease progression [1, 35–37].”
From microRNA-132 attenuates inflammation in induced pluripotent stem cell-derived microglia from Alzheimer’s disease patients (2026) · cites this paper as [35]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Galectin-3 (Gal-3) is a key protein involved in neuroinflammation and is strongly upregulated in neurodegenerative conditions16.”
From Deletion of SPI1 in microglia exacerbates amyloid pathology by impairing microglial response in Alzheimer’s disease models (2026) · cites this paper as [16]
Experimental — accuracy not yet measuredIn the citing paper
“Neuroinflammation is a common feature of AD9 and GWAS have associated several immune-related genes with AD including ABCA7, CD33, CLU, CR1, MS4A10, 11 and recently TREM2.12, 13”
From Whole-genome sequencing suggests a chemokine gene cluster that modifies age at onset in familial Alzheimer's disease (2015) · cites this paper as [9]
In the citing paper
“Clinical evidence shows that TauO and brain inflammation also appear in the preclinical or prodromal AD stage, many decades prior to the onset of dementia. 100”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [100]
In the citing paper
“Furthermore, since the immune response exists throughout the pathological progress of AD [104, 105], suggesting that it may also participate in and aggravate the disease development.”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [104]
In the citing paper
“Plaques were evident in multiple brain regions by 4mo in male and female 5xFAD mice, concomitant with the stereotypical activation and gliosis of plaque- and non-plaque-associated microglia (PAM and NPAM, respectively; Fig. 1A-C) [52, 53].”
From Microglia facilitate loss of perineuronal nets in the Alzheimer's disease brain (2020) · cites this paper as [52]
In the citing paper
“The neurotoxicity of microglial cells may also be related to their expression of tau, which is triggered by the deposition of Aβ in the brain and is known to be neurotoxic149.”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [149]
In the citing paper
“In AD brains reactive microglia has been found colocalized with amyloid plaques. In addition, the reactive astrocytes accumulate around senile plaques next to the activated microglia (Heneka et al., 2015).”
From The role of microglia in retinal neurodegeneration: Alzheimer’s disease, parkinson, and glaucoma. (2017) · cites this paper as Heneka et al., 2015
In the citing paper
“The sustained exposure to cytokines, chemokines and Aβ, could be responsible for the functional impairment of microglial cells located around Aβ− deposits (Heneka et al., 2015).”
From The role of microglia in retinal neurodegeneration: Alzheimer’s disease, parkinson, and glaucoma. (2017) · cites this paper as Heneka et al., 2015
In the citing paper
“Microglial senescence can enhance the sensitivity of microglia to inflammatory stimuli; this phenomenon is called “priming” (Heneka et al., 2015).”
From The role of microglia in retinal neurodegeneration: Alzheimer’s disease, parkinson, and glaucoma. (2017) · cites this paper as Heneka et al., 2015
In the citing paper
“Popular neuroprotective strategies for AD management consist of discovering small molecules with the ability to block these Aβ interactions with intracellular and extracellular targets to avoid caspase activation and the expression of proapoptotic proteins, to reduce the stress kinase signaling cascades, to inhibit tau protein phosphorylation, to counterpoise cholinergic functional loss, and to bo”
From The Multifaceted Role of Neuroprotective Plants in Alzheimer’s Disease Treatment (2022) · cites this paper as [37]
In the citing paper
“The FDA has approved two drugs for mild cognitive impairment (MCI) to early, mild stages of AD after years of failed clinical trials. They are aducanemab, and lecanemab, among which aducanemab received accelerated approval [14, 15].”
From Current therapeutics for Alzheimer’s disease and clinical trials (2024) · cites this paper as [15]
In the citing paper
“Neuroinflammation and oxidative stress (OS) are undoubtedly hallmarks of neurodegeneration, contributing to disease progression.”
From ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease (2020) · cites this paper as [42]
In the citing paper
“These genetic findings are further supported by the common observation of aberrantly activated microglia in pathologically relevant AD brain regions, including within and surrounding Aβ plaques [59, 60].”
From Systems-based proteomics to resolve the biology of Alzheimer’s disease beyond amyloid and tau (2021) · cites this paper as [60]
In the citing paper
“Indeed, many of the risk genes associated with AD mediate their effects through microglia, the brain‐resident macrophages (Glass et al, 2010; Heneka et al, 2015; Nott et al, 2019).”
From Mechanisms of DNA damage-mediated neurotoxicity in neurodegenerative disease (2022) · cites this paper as Heneka et al, 2015
In the citing paper
“Neuroinflammation has been identified as a key contributor to the pathobiology of AD [2–4]”
In the citing paper
“and occurs at early disease stages [2, 5–7]”
In the citing paper
“Peripheral inflammation may exacerbate neuroinflammation [2].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,526
Glutamate neurotoxicity and diseases of the nervous system
Choi, D. W. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 8,188
The chemokine system in diverse forms of macrophage activation and polarization
MANTOVANI, A., SICA, A., SOZZANI, S., ALLAVENA, P., VECCHI, A., & LOCATI, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.09.015 · Cited by 6,534
Iliff, J. J., Wang, M., Liao, Y., Plogg, B. A., Peng, W., Gundersen, G. A., Benveniste, H., Vates, G. E., Deane, R., Goldman, S. A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003748 · Cited by 5,824
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528
Schroder, K., & Tschopp, J. (2010) · Cell · doi:10.1016/j.cell.2010.01.040 · Cited by 5,475
Astrocytes: Biology and pathology
Sofroniew, M. V., & Vinters, H. V. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0619-8 · Cited by 5,196
Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages
Ginhoux, F., Greter, M., Leboeuf, M., Nandi, S., See, P., Gokhan, S., Mehler, M. F., Conway, S. J., Ng, L. G., Stanley, E. R., et al. (2010) · Science · doi:10.1126/science.1194637 · Cited by 5,175
Richness of human gut microbiome correlates with metabolic markers
Le Chatelier, E., Nielsen, T., Qin, J., Prifti, E., Hildebrand, F., Falony, G., Almeida, M., Arumugam, M., Batto, J.-M., Kennedy, S., et al. (2013) · Nature · doi:10.1038/nature12506 · Cited by 4,662
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Cited by
Sorted by citations
Items 401–500 of 1,118
CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia
Abu‐Rumeileh, S., Steinacker, P., Polischi, B., Mammana, A., Bartoletti‐Stella, A., Oeckl, P., Baiardi, S., Zenesini, C., Huss, A. M., Cortelli, P., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0562-4 · Cited by 157
PET Imaging of Neuroinflammation in Alzheimer’s Disease
Zhou, R., Ji, B., Kong, Y., Qin, L., Ren, W., Guan, Y., & Ni, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.739130 · Cited by 157
Microglial amyloid beta clearance is driven by PIEZO1 channels
Jäntti, H., Sitnikova, V., Ishchenko, Y., Shakirzyanova, A., Giudice, L., Ugidos, I. F., Gómez‐Budia, M., Korvenlaita, N., Ohtonen, S., Belaya, I., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02486-y · Cited by 164
Inflammatory pathways in Alzheimer’s disease mediated by gut microbiota
Qian, X.-H., Song, X.-X., Liu, X.-L., Chen, S.-D., & Tang, H.-D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101317 · Cited by 153
Microglial dysfunction connects depression and Alzheimer’s disease
Santos, L. E., Beckman, D., & Ferreira, S. T. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.11.011 · Cited by 154
Manda‐Handzlik, A., & Demkow, U. A. (2019) · Cells · doi:10.3390/cells8121477 · Cited by 154
Innate and adaptive immune responses in the CNS
Waisman, A., Liblau, R., & Becher, B. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00141-6 · Cited by 158
Exosomes in Alzheimer's disease
Malm, T., Loppi, S. H., & Kanninen, K. M. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2016.04.011 · Cited by 152
Dystrophic microglia in late‐onset Alzheimer's disease
Streit, W. J., Khoshbouei, H., & Bechmann, I. (2020) · Glia · doi:10.1002/glia.23782 · Cited by 152
Brahmi (Bacopa monnieri): An ayurvedic herb against the Alzheimer's disease
Dubey, T., & Chinnathambi, S. (2019) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2019.108153 · Cited by 151
LRP1 modulates the microglial immune response via regulation of JNK and NF‐ΚB signaling pathways
Yang, L., Liu, C.-C., Zheng, H., Kanekiyo, T., Atagi, Y., Jia, L., Wang, D., N’songo, A., Can, D., Xu, H., et al. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0772-7 · Cited by 129
Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments
Jung, Y. J., Tweedie, D., Scerba, M. T., & Greig, N. H. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00313 · Cited by 156
Herbert, J., & Lucassen, P. J. (2016) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2015.12.001 · Cited by 150
Cellular cholesterol homeostasis and Alzheimer’s disease
Chang, T.-Y., Yamauchi, Y., Hasan, M. T., & Chang, C. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075630 · Cited by 155
The Role of Biomarkers in Alzheimer’s Disease Drug Development
Cummings, J. L. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-05542-4_2 · Cited by 153
Dourado, N. S., Souza, C. D. S., de Almeida, M. M. A., da Silva, A. B., dos Santos, B. L., da Silva, V. D. A., de Assis, A. M., da Silva, J. S., Souza, D. O., Costa, M. D. F. D., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00119 · Cited by 159
Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention
Mahaman, Y. A. R., Embaye, K. S., Huang, F., Li, L., Zhu, F., Wang, J.-Z., Liu, R., Feng, J., & Wang, X. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101544 · Cited by 149
Zhang, M., Cheng, Q., Zheng, Z., Qian, F., Wang, Y., Thu, P. M., Zhang, X., Zhou, Y., Tu, L., Liu, Q., et al. (2018) · Theranostics · doi:10.7150/thno.26164 · Cited by 148
Stefanovski, L., Triebkorn, P., Spiegler, A., Díaz-Cortés, M.-A., Solodkin, A., Jirsa, V., McIntosh, A. R., Ritter, P., & Initiative, A. D. N. (2019) · Frontiers in Computational Neuroscience · doi:10.3389/fncom.2019.00054 · Cited by 145
Plazas, E., Murillo, M. C. Á., Muñoz-Cendales, D. R., & Suárez, L. E. C. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106126 · Cited by 152
Klotho controls the brain-immune system interface in the choroid plexus
Zhu, L., Stein, L. R., Kim, D., Ho, K., Yu, G.-Q., Zhan, L., Larsson, T. E., & Mucke, L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1808609115 · Cited by 148
Neuroinflammation, gut microbiome, and Alzheimer's disease
Lin, L., Zheng, L. J., & Zhang, L. J. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0983-2 · Cited by 147
C9orf72 deficiency promotes microglial-mediated synaptic loss in aging and amyloid accumulation
Lall, D., Lorenzini, I., Mota, T. A., Bell, S., Mahan, T. E., Ulrich, J. D., Davtyan, H., Rexach, J. E., Muhammad, A. K. M. G., Shelest, O., et al. (2021) · Neuron · doi:10.1016/j.neuron.2021.05.020 · Cited by 147
Liu, Q., Chen, Y., Shen, C., Xiao, Y., Wang, Y., Liu, Z., & Liu, X. (2016) · The FASEB Journal · doi:10.1096/fj.201601071r · Cited by 147
Chen, C., & Nakagawa, S. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101868 · Cited by 178
van den Bos, H., Spierings, D. C. J., Taudt, A., Bakker, B., Porubskỳ, D., Falconer, E., Novoa, C. A., Halsema, N., Kazemier, H. G., Hoekstra-Wakker, K., et al. (2016) · Genome biology · doi:10.1186/s13059-016-0976-2 · Cited by 139
Millan, M. J. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.03.004 · Cited by 151
Jeong, A., Suazo, K. F., Wood, W. G., Distefano, M. D., & Li, L. (2018) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2018.1458070 · Cited by 152
The role of sleep deprivation and circadian rhythm disruption as risk factors of Alzheimer’s disease
Wu, H., Dunnett, S. L., Ho, J. Y. S., & Chang, R. C. (2019) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2019.100764 · Cited by 154
Liu, Y., Chu, J. M. T., Yan, T., Zhang, Y., Chen, Y., Chang, R. C., & Wong, G. T. C. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1653-7 · Cited by 156
Bhatti, G. K., Reddy, A. P., Reddy, P. H., & Bhatti, J. S. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00369 · Cited by 145
Astroglia dynamics in ageing and Alzheimer's disease
Verkhratsky, A., Zorec, R., Rodriguez, J. J., & Parpura, V. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.09.011 · Cited by 150
Self-citationBrendel, M., Probst, F., Jaworska, A. M., Overhoff, F., Korzhova, V., Albert, N. L., Beck, R., Lindner, S., Gildehaus, F., Baumann, K., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.167858 · Cited by 145
Cardiometabolic multimorbidity and incident dementia: the Swedish twin registry
Dove, A. E., Guo, J., Marseglia, A., Fastbom, J., Vetrano, D. L., Fratiglioni, L., Pedersen, N. L., & Xu, W. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac744 · Cited by 152
Neuroinflammatory responses in Alzheimer’s disease
Dansokho, C., & Heneka, M. T. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1831-7 · Cited by 146
Self-citationPapadimitriou, C., Celikkaya, H., Cosacak, M. I., Mashkaryan, V., Bray, L., Bhattarai, P., Brandt, K., Hollak, H., Chen, X., He, S., et al. (2018) · Developmental Cell · doi:10.1016/j.devcel.2018.06.005 · Cited by 143
Guo, Z., Chen, Y., Mao, Y., Zheng, T., Jiang, Y., Yan, Y., Yin, X., & Zhang, B. (2017) · Scientific Reports · doi:10.1038/srep45971 · Cited by 150
Advances in Alzheimer’s Diagnosis and Therapy: The Implications of Nanotechnology
Hajipour, M. J., Santoso, M. R., Rezaee, F., Aghaverdi, H., Mahmoudi, M., & Perry, G. L. (2017) · Trends in biotechnology · doi:10.1016/j.tibtech.2017.06.002 · Cited by 144
The Amygdala as a Locus of Pathologic Misfolding in Neurodegenerative Diseases
Nelson, P. T., Abner, E. L., Patel, E., Anderson, S., Wilcock, D. M., Kryscio, R. J., Eldik, L. J. V., Jicha, G. A., Gal, Z. T., Nelson, R. S., et al. (2017) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlx099 · Cited by 141
Gupta, V. B., Chitranshi, N., den Haan, J., Mirzaei, M., You, Y., Lim, J. K. H., Basavarajappa, D. K., Godinez, A., Angelantonio, S. D., Sachdev, P. S., et al. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100899 · Cited by 149
Signal pathways in the treatment of Alzheimer’s disease with traditional Chinese medicine
Ding, M.-R., Qu, Y.-J., Hu, B., & An, H. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113208 · Cited by 145
Hafner‐Bratkovič, I., Sušjan, P., Lainšček, D., Tapia‐Abellán, A., Cerović, K., Kadunc, L., Angosto-Bazarra, D., Pelegrı́n, P., & Jerala, R. (2018) · Nature Communications · doi:10.1038/s41467-018-07573-4 · Cited by 145
The Immunopathogenesis of Alzheimer’s Disease Is Related to the Composition of Gut Microbiota
Leblhuber, F., Ehrlich, D., Steiner, K., Geisler, S., Fuchs, D., Lanser, L., & Kurz, K. (2021) · Nutrients · doi:10.3390/nu13020361 · Cited by 149
Hartmann, K., Sepulveda-Falla, D., Rose, I. V. L., Madore, C., Muth, C., Matschke, J., Butovsky, O., Liddelow, S., Glatzel, M., & Krasemann, S. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0735-1 · Cited by 141
Current and emerging avenues for Alzheimer's disease drug targets
Loera‐Valencia, R., Cedazo-Mínguez, Á., Kenigsberg, P.-A., Page, G., Duarte, A. I., Giusti, P., Zusso, M., Robert, P. H., Frisoni, G. B., Cattaneo, A., et al. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12959 · Cited by 142
Sustainable Drug Discovery of Multi-Target-Directed Ligands for Alzheimer’s Disease
Rossi, M., Freschi, M., Nascente, L. D. C., Salerno, A., Teixeira, S. D. M. V., Nachon, F., Chantegreil, F., Soukup, O., Prchal, L., Malaguti, M., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00048 · Cited by 142
Rusek, M., Smith, J., El-Khatib, K., Aikins, K., Czuczwar, S. J., & Pluta, R. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010864 · Cited by 151
Post-mortem assessment in vascular dementia: advances and aspirations
McAleese, K. E., Alafuzoff, I. I., Charidimou, A., Reuck, J. D., Grinberg, L. T., Hainsworth, A. H., Hortobágyi, T., Ince, P. G., Jellinger, K. A., Gao, J., et al. (2016) · BMC Medicine · doi:10.1186/s12916-016-0676-5 · Cited by 144
Alpha-2 macroglobulin in Alzheimer’s disease: a marker of neuronal injury through the RCAN1 pathway
Varma, V. R., Varma, S., An, Y., Hohman, T. J., Seddighi, S., Casanova, R., Beri, A., Dammer, E. B., Seyfried, N. T., Pletniková, O., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.206 · Cited by 146
Reconsideration of Anticholinesterase Therapeutic Strategies against Alzheimer’s Disease
Wang, H., & Zhang, H. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00391 · Cited by 142
The Neurovascular Unit Dysfunction in Alzheimer’s Disease
Soto-Rojas, L. O., Pacheco‐Herrero, M., Martínez-Gómez, P. A., Campa-Córdoba, B. B., Apátiga-Pérez, R., Villegas-Rojas, M. M., Harrington, C. R., de la Cruz, F., Garcés‐Ramírez, L., & Luna‐Muñoz, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042022 · Cited by 146
Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease
Ferrari‐Souza, J. P., Ferreira, P. C. L., Bellaver, B., Tissot, C., Wang, Y.-T., Leffa, D. T., Brum, W. S., Benedet, A. L., Ashton, N. J., Bastiani, M. A. D., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01716-2 · Cited by 150
Zhou, J., Yu, W., Zhang, M., Tian, X., Li, Y., & Lü, Y. (2019) · Neurochemical Research · doi:10.1007/s11064-019-02748-x · Cited by 139
Zhang, L., Silva, T. C., Young, J. I., Gomez, L., Schmidt, M. A., Hamilton-Nelson, K. L., Kunkle, B. W., Chen, X., Martin, E. R., & Wang, L. (2020) · Nature Communications · doi:10.1038/s41467-020-19791-w · Cited by 139
Dozio, V., & Sanchez, J. (2017) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2017.1302705 · Cited by 137
Dorninger, F., Forss‐Petter, S., Wimmer, I., & Berger, J. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105061 · Cited by 152
COVID-19 and Alzheimer’s disease: how one crisis worsens the other
Xia, X., Wang, Y., & Zheng, J. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00237-2 · Cited by 138
Hoeijmakers, L., Ruigrok, S. R., Amelianchik, A., Ivan, D., van Dam, A.-M., Lucassen, P. J., & Korosi, A. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.12.023 · Cited by 138
Gong, T., Chen, Q., Mao, H., Zhang, Y., Ren, H., Xu, M., Chen, H., & Yang, D. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.925435 · Cited by 138
Ovais, M., Zia, N., Ahmad, I., Khalil, A. T., Raza, A., Ayaz, M., Sadiq, A., Ullah, F., & Shinwari, Z. K. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00284 · Cited by 140
Peroxisome quality control and dysregulated lipid metabolism in neurodegenerative diseases
Jo, D. S., Park, N. Y., & Cho, D. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00503-9 · Cited by 143
Lin, Y., Jin, J., Lv, R., Luo, Y. M., Dai, W.-P., Li, W., Tang, Y., Wang, Y., Ye, X., & Lin, W. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01198-3 · Cited by 149
Hulle, C. V., Jonaitis, E. M., Betthauser, T. J., Batrla, R., Wild, N., Kollmorgen, G., Andréasson, U., Okonkwo, O. C., Bendlin, B. B., Asthana, S., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12204 · Cited by 132
Liu, P., Zhang, T., Chen, Q., Li, C., Chu, Y., Guo, Q., Zhang, Y., Zhou, W., Chen, H., Zhou, Z., et al. (2021) · Advanced Materials · doi:10.1002/adma.202100746 · Cited by 140
Inflammatory aspects of Alzheimer’s disease
Lucena, P. B., & Heneka, M. T. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02790-2 · Cited by 152
Self-citationMarkers of neuroinflammation associated with Alzheimer’s disease pathology in older adults
Popp, J., Oikonomidi, A., Tautvydaitė, D., Dayon, L., Bacher, M., Migliavacca, E., Henry, H., Kirkland, R., Severin, I., Wojcik, J., et al. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.01.020 · Cited by 136
Drug development for alzheimer’s disease: Microglia induced neuroinflammation as a target
Dong, Y., Li, X., Cheng, J., & Hou, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030558 · Cited by 136
Comorbidities in rosacea: A systematic review and update
Haber, R., & Gemayel, M. E. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.09.016 · Cited by 136
Fu, W., Wang, X., & Ip, N. Y. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00402 · Cited by 138
Inflammation in Neurological Disorders: The Thin Boundary Between Brain and Periphery
Cervellati, C., Trentini, A., Pecorelli, A., & Valacchi, G. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8076 · Cited by 140
Tang, J., Huang, L.-F., Deng, J., Wang, Y., Guo, C., Peng, X.-N., Liu, Z., & Gao, J. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102229 · Cited by 132
Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions
Seto, M., Weiner, R. L., Dumitrescu, L., & Hohman, T. J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00452-5 · Cited by 135
Overview of anti-inflammatory diets and their promising effects on non-communicable diseases
Yu, X., Pu, H., & Voss, M. (2024) · British Journal of Nutrition · doi:10.1017/s0007114524001405 · Cited by 134
Brain Renin–Angiotensin System at the Intersect of Physical and Cognitive Frailty
Cosarderelioglu, C., Nidadavolu, L. S., George, C. J., Oh, E. S., Bennett, D. A., Walston, J. D., & Abadir, P. M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.586314 · Cited by 134
Behl, T., Makkar, R., Sehgal, A., Singh, S., Sharma, N., Zengin, G., BUNGAU, S. G., Andronie-Cioară, F. L., Munteanu, M. A., Brisc, M. C., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147432 · Cited by 134
The endocytic pathway in microglia during health, aging and Alzheimer’s disease
Solé-Domènech, S., Cruz, D. L., Capetillo-Zarate, E., & Maxfield, F. R. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.07.002 · Cited by 133
The Future of Precision Medicine in the Cure of Alzheimer’s Disease
Arafah, A., Khatoon, S., Rasool, I., Khan, A., Rather, M. A., Abujabal, K. A., Faqih, Y. A. H., Rashid, H., Rashid, S. M., Bilal Ahmad, S., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11020335 · Cited by 133
Li, S.-P., Wang, Y., Qi, S., Zhang, Y., Deng, G., Ding, W.-Z., Ma, C., Lin, Q., Guan, H., Liu, W., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00346 · Cited by 134
Hall, B., Mak, E., Cervenka, S., Aigbirhio, F. I., Rowe, J. B., & O’Brien, J. T. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.03.002 · Cited by 132
The Second Brain: Is the Gut Microbiota a Link Between Obesity and Central Nervous System Disorders?
Ochoa‐Repáraz, J., & Kasper, L. H. (2016) · Current Obesity Reports · doi:10.1007/s13679-016-0191-1 · Cited by 141
CB2 Cannabinoid Receptor As Potential Target against Alzheimer's Disease
Aso, E., & Ferrer, I. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00243 · Cited by 131
Ma, P., Li, Y., Zhang, W., Fang, F., Sun, J., Liu, M., Li, K., & Dong, L. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190725130134 · Cited by 132
Soluble α-synuclein–antibody complexes activate the NLRP3 inflammasome in hiPSC-derived microglia
Trudler, D., Nazor, K. L., Eisele, Y. S., Grabauskas, T., Dolatabadi, N., Parker, J., Sultan, A., Zhong, Z., Goodwin, M. S., Levites, Y., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025847118 · Cited by 137
Neuroinflammation: The central enabler of postoperative cognitive dysfunction
Liu, Y., Yang, W., Xue, J., Chen, J., Liu, S., Zhang, S., Zhang, X., Gu, X., Dong, Y., & Qiu, P. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115582 · Cited by 139
An exhausted-like microglial population accumulates in aged and APOE4 genotype Alzheimer’s brains
Millet, A., Ledo, J. H., & Tavazoie, S. F. (2024) · Immunity · doi:10.1016/j.immuni.2023.12.001 · Cited by 132
Lithium deficiency and the onset of Alzheimer’s disease
Aron, L., Ngian, Z., Qiu, C., Choi, J., Liang, M., Drake, D., Hamplova, S. E., Lacey, E. K., Roche, P., Yuan, M., et al. (2025) · Nature · doi:10.1038/s41586-025-09335-x · Cited by 153
Park, T., Chen, H., Kevala, K., Lee, J.-W., & Kim, H.-Y. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0751-z · Cited by 131
Mitophagy and cGAS–STING crosstalk in neuroinflammation
Zhou, X., Wang, J., Yu, L., Qiao, G., Qin, D., Yuen-Kwan Law, B., Ren, F., Wu, J., & Wu, A. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.05.012 · Cited by 131
The Lipoxygenases: Their Regulation and Implication in Alzheimer’s Disease
Czapski, G. A., Czubowicz, K., Strosznajder, J. B., & Strosznajder, R. P. (2015) · Neurochemical Research · doi:10.1007/s11064-015-1776-x · Cited by 137
Neuroinflammation, Mast Cells, and Glia: Dangerous Liaisons
Skaper, S. D., Facci, L., Zusso, M., & Giusti, P. (2017) · The Neuroscientist · doi:10.1177/1073858416687249 · Cited by 133
P2Y1 receptor blockade normalizes network dysfunction and cognition in an Alzheimer’s disease model
Reichenbach, N., Delekate, A., Breithausen, B., Keppler, K., Poll, S., Schulte, T., Peter, J., Plescher, M., Hansen, J. N., Blank, N., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171487 · Cited by 131
Self-citationScheltens, P., Hallikainen, M., Grimmer, T., Duning, T., Gouw, A. A., Teunissen, C. E., Wink, A. M., Maruff, P., Harrison, J., van Baal, C. M., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0431-6 · Cited by 129
Developing Effective Alzheimer’s Disease Therapies: Clinical Experience and Future Directions
Elmaleh, D. R., Farlow, M. R., Conti, P. S., Tompkins, R. G., Kundakovic, L., & Tanzi, R. E. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190507 · Cited by 129
Mechanisms of DNA damage-mediated neurotoxicity in neurodegenerative disease
Welch, G., & Tsai, L. (2022) · The EMBO Reports · doi:10.15252/embr.202154217 · Cited by 129
Copper Exposure Perturbs Brain Inflammatory Responses and Impairs Clearance of Amyloid-Beta
Kitazawa, M., Hsu, H.-W., & Medeiros, R. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfw081 · Cited by 129
Steinacker, P., Verde, F., Fang, L., Feneberg, E., Oeckl, P., Roeber, S., Anderl-Straub, S., Danek, A., Diehl-Schmid, J., Fassbender, K., et al. (2018) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-317138 · Cited by 129
Hampel, H., Toschi, N., Baldacci, F., Zetterberg, H., Blennow, K., Kilimann, I., Teipel, S. J., Cavedo, E., Melo dos Santos, A., Epelbaum, S., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.11.015 · Cited by 129
A neuroprotective astrocyte state is induced by neuronal signal EphB1 but fails in ALS models
Tyzack, G. E., Hall, C. E., Sibley, C. R., Cymes, T., Forostyak, S., Carlino, G., Meyer, I. F., Schiavo, G., Zhang, S.-C., Gibbons, G. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01283-z · Cited by 128
Jacobs, K. R., Lim, C. K., Blennow, K., Zetterberg, H., Chatterjee, P., Martins, R. N., Brew, B. J., Guillemin, G. J., & Lovejoy, D. B. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.03.015 · Cited by 130
Cerovic, M., Forloni, G., & Balducci, C. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00284 · Cited by 127
Metadata
- Authors
- Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., Herrup, K., Frautschy, S. A., Finsen, B., Brown, G. C., Verkhratsky, A., Yamanaka, K., Koistinaho, J., Latz, E., Halle, A., Petzold, G. C., Town, T., Morgan, D., Shinohara, M. L., Perry, V. H., Holmes, C., Bazan, N. G., Brooks, D. J., Hunot, S., Joseph, B., Deigendesch, N., Garaschuk, O., Boddeke, E., Dinarello, C. A., Breitner, J. C., Cole, G. M., Golenbock, D. T., & Kummer, M. P.
- Affiliations
- University of Bonn (DE)
- University of California, Riverside (US)
- Case Western Reserve University (US)
- German Center for Neurodegenerative Diseases (DE)
- University of Illinois Chicago (US)
- University of Münster (DE)
- Cleveland Clinic (US)
- Hong Kong University of Science and Technology (HK)
- University of California, Los Angeles (US)
- University of Southern Denmark (DK)
- University of Cambridge (GB)
- Ikerbasque (ES)
- RIKEN (JP)
- Center of Advanced European Studies and Research (DE)
- University of Southern California (US)
- Duke Medical Center (US)
- Southampton General Hospital (GB)
- Southern Health NHS Foundation Trust (GB)
- Louisiana State University (US)
- Hammersmith Hospital (GB)
- Centre National de la Recherche Scientifique (FR)
- Karolinska Institutet (SE)
- Max Planck Institute for Infection Biology (DE)
- University of Tübingen (DE)
- University Medical Center Groningen (NL)
- University of Colorado Denver (US)
- Douglas Mental Health University Institute (CA)
- University of Massachusetts Chan Medical School (US)
- Corresponding author
- Heneka, Michael T
- ORCID
- Heneka, Michael T
- Carson, Monica J
- Landreth, Gary E
- Brosseron, Frederic
- Feinstein, Douglas L
- Jacobs, Andreas H
- Ransohoff, Richard M
- Herrup, Karl
- Frautschy, Sally A
- Finsen, Bente
- Brown, Guy C
- Verkhratsky, Alexei
- Yamanaka, Koji
- Latz, Eicke
- Halle, Annett
- Petzold, Gabor C
- Shinohara, Mari L
- Perry, V Hugh
- Holmes, Clive
- Bazan, Nicolas G
- Brooks, David J
- Hunot, Stéphane
- Joseph, Bertrand
- Deigendesch, Nikolaus
- Garaschuk, Olga
- Boddeke, Erik
- Dinarello, Charles A
- Breitner, John C
- Golenbock, Douglas T
- Kummer, Markus P
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 14
- Issue
- 4
- Pages
- 388-405
- ISSN
- 1474-4422 (ISSN-L)
- PMC
- PMC5909703
- OpenAlex
- W2087243986
- Cited by
- 6,226
- References
- 244
- Citations by year
- 2026: 686 · 2025: 708 · 2024: 713 · 2023: 640 · 2022: 665 · 2021: 620 · 2020: 554 · 2019: 506 · 2018: 406 · 2017: 342 · 2016: 259 · 2015: 110
- FWCI
- 29.69
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion)
- The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion)
- HAL (submittedVersion, other-oa)
- Max Planck Digital Library (submittedVersion)
- Deposito de Investigacion Universidad de Sevilla (University of Seville) (submittedVersion, cc-by-nc-nd)
- DZNE Pub (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Funders
- Medical Research Council (MR/L010593/1)
- Japan Society for the Promotion of Science (26293208)
- National Institute on Aging (R21AG053884)
- National Institute of Neurological Disorders and Stroke (R01NS059005, R01NS076794)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, neuroinflammation, innate immunity, microglia, astrocytes, pattern recognition receptors, protein aggregation, misfolded proteins, inflammatory mediators, systemic inflammation, obesity, genetic risk factors, therapeutic target
- MeSH terms
- Alzheimer Disease, Animals, Anti-Inflammatory Agents, Non-Steroidal, Astrocytes, Brain Injuries, Clinical Trials as Topic, Disease Models, Animal, Humans, Immunity, Innate, Immunization, Inflammation, Locus Coeruleus, Obesity, Phagocytosis, Risk Factors, Severity of Illness Index, Biomarkers, Protein Folding, Microglia, Disease Progression, Nootropic Agents, Inflammation Mediators
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
